WeightControl.com: What should readers take away from your report?
Response: SGLT2 inhibitors, from being merely an antidiabetic drug, are contributing a lot to the global fight against cardiovascular and renal diseases, and their use is strikingly increasing due to a high safety profile and evident benefits, mostly in patients experiencing heart failure.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: Based on this review, which takes into account the most important trials with this class of drugs, a potential area of research can focus on a synergistic interaction between SGLT2 inhibitors and other antidiabetic agents like GLP-1 receptor agonists or DPP-4 inhibitors; another area which should be better analyzed, is the role of this class of drugs in conjunction with other cardiovascular drugs, especially diuretics.
We have no disclosures as regards this manuscript and interview.
Citation: Khater, Jacinthea,b; Malakouti, Saraa; Khoury, Antoine Ela,c; Cortese, Bernardoa,d. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease. Journal of Cardiovascular Medicine ():10.2459/JCM.0000000000001598, February 01, 2024. | DOI: 10.2459/JCM.0000000000001598
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on February 19, 2024 by weightcontrol